[Radiofrequency ablation in benign bone tumors]
Argento F, Augustovski F, Alcaraz A, Pichon-Riviere A, García Martí S, Bardach A, Ciapponi A.
Record ID 32018001584
Spanish
Original Title:
Ablación por radiofrecuencia en tumores óseos benignos
Authors' recommendations:
Low-quality evidence from observational studies suggests that radiofrequency ablation might be effective in treating benign bone tumors, and similar to surgery. In addition, it might help reduce hospitalization periods and length of the intervention required.
Institutions like the Cardiovascular and Interventional Radiology Society of Europe and the United Kingdom Royal College of Radiologists consider radiofrequency ablation as an initial therapeutic approach to benign bone tumors. The United States Society of Interventional Radiology has established this technology as first-line therapy for osteoid osteomas and as an alternative for other benign bone tumors.
Public health funders from Brazil and the United Kingdome and private health funders from the United States cover this technology for the treatment of osteoid osteoma. No studies assessing the cost-effectiveness of this technology for the indications assessed have been found in the region.
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Radiofrequency Ablation
- Bone Neoplasms
- Cancer Pain
- Pain Management
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.